Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parabilis MedicinesPBLS -4.66%10 Pretax Margin % is % as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Parabilis Medicines ranks worse than 106157.01% on this metric.
The historical rank and industry rank for Parabilis Medicines's Pretax Margin % or its related term are showing as below:
PBLS's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.895 * Ranked among companies with meaningful Pretax Margin % only.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Parabilis Medicines Pretax Margin % Related Terms
Parabilis Medicines Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines Pretax Margin % Chart
Parabilis Medicines Annual Data
Trend
Dec24
Dec25
Pretax Margin %
0.00
0.00
Parabilis Medicines Semi-Annual Data
Dec24
Dec25
Pretax Margin %
0.00
0.00
PBLS vs IDYA, ELVN, BEAM: Pretax Margin % Comparison
For the Biotechnology subindustry, Parabilis Medicines's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parabilis Medicines Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Parabilis Medicines's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines (PBLS) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Parabilis Medicines and its competitors. According to the industry distribution chart, Parabilis Medicines ranks #999999 out of 942 companies in the Biotechnology industry.
Is Parabilis Medicines' Pretax Margin % too high?
Parabilis Medicines' current Pretax Margin % is %. Based on the distribution chart, Parabilis Medicines ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Pretax Margin % compare to IDYA and ELVN?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #999999 out of 942 companies for Pretax Margin %. This places Parabilis Medicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Parabilis Medicines and its competitors. Parabilis Medicines's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Pretax Margin % of %. The current Pretax Margin % is %. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
